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A B S T R A C T
Background: Brucella is a Gram-negative and facultative intracellular organism that causes brucellosis, a
common zoonotic disease. Over 500,000 people are annually aﬀected by brucellosis. Brucella is highly infectious
through inhalation route; for this reason it is used for biological warfare aims. This study aimed to study the
serum bactericidal and splenic activity of Total-OMP-r CagA immunogens from Brucella abortus and Helicobacter
pylori in a BALB/c mouse model.
Methods: Immunization of BALB/c mice was performed with immunogenic proteins three times subcutaneously
(S.C.) at 14-day intervals. The protective eﬀects of two component vaccines with CpG adjuvant were evaluated
after mice were challenged with H. pylori ss1 and Brucella abortus strain 544. The speciﬁc IgG1 and IgG2a
antibodies in sera were assessed using ELISA test. For measuring the antigen-speciﬁc IL-4, IL-12 and IFN-γ
responses in sera of immunized mice after challenge, RT-PCR technique was applied. Twenty days after the
challenge, mice were killed then gastric, splenic and serum samples were assessed and bacterial colony count
was measured based on the pour plate count agar.
Results: The results indicated that rCagA + OMP decreased bacterial colonization in these tissues, and sig-
niﬁcant diﬀerence was observed between test and control groups (p value˂0.001).
Conclusion: Our results showed that the combination vaccine was eﬀective against an oral exposure and the
bacterial burden in the spleen, serum and gastric tissues were reduced in mice immunized with the Total- OMP-
CagA.
1. Introduction
Brucellosis is a widespread zoonotic disease mainly transmitted
through cattle, sheep, goats, pigs and camels or direct contact with
blood, placenta, fetuses or uterine secretions, consumption of con-
taminated raw animal products [1]. Over 500,000 people are annually
contaminated with infections are caused by this bacterium [2]. Brucella
spp., is highly infectious through aerosol route, for this reason, it as an
attractive pathogen to be used as a potential agent for biological
warfare purposes [3]. Brucellosis there is around the world [4]. The
prevalence of brucellosis is growing due to the international tourism
and migration [5]. Brucellosis has a high frequency of morbidity both in
humans and animals; and this organism has a high health and economic
burden especially in developing countries [6]. Methods of prevention
are health education to decrease occupational and food-borne risks, and
pasteurization of dairy products. However, ﬁnal prevention of human
infection depended on the elimination of the infection among domestic
animals. This purpose can probably be obtained by an appropriate
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immunization of animals as well as elimination of infected animals [7].
Recently there are many vaccines for application in humans and ani-
mals, but none of those are quite safe and their eﬃcacy isn't 100% [8].
Outer membrane proteins (OMPs) of Brucella are virulence factors of
this organism and play a signiﬁcant role in pathogenesis of Brucella,
nowadays are raised as one of the important vaccine candidates [9].
The role of H. pylori in gastric cancer has been veriﬁed and many factors
have been recognized in association to the pathogenicity of this bac-
terium, the cagA gene has been detected in about 80%–100% of H.
pylori strains isolated from people with gastric cancer [10]. Therefore,
due to the lack of safe and more eﬀective vaccine against Brucella, this
study aimed to evaluate the serum bactericidal and splenic activity of
Total-OMP- rCagA combination from B. abortus and H. pylori in BALB/c
Mouse model.
2. Material and methods
2.1. Ethics statement
All experimental protocols with animals were carried out in ﬁrm
consistent with international ethical standards for animal experi-
mentation (Helsinki Declaration and its amendments, Amsterdam
Protocol of welfare and animal protection and National Institutes of
Health, USANIH, and guidelines).
2.2. Mice and bacterial strains
Six-to eight-week-old female BALB/c mice were purchased from the
Pasteur institute, Tehran. OMP proteins were prepared of B. abortus S1
and for challenging were used of B. abortus 544 biovar 1. S19 strain was
provided from Razi Institute and other strains were prepared of Pasteur
Institute, Tehran.
2.3. Extraction of OMPs B. abortus strain S19
Broth cultures containing bacteria were centrifuged for 4min at
6000 rpm and the sedimentation resolved in 10mm Tris buﬀer solution.
2.1 mm PMSF, lysozyme (10mg per gram of bacteria) and 1mm EDTA
were added to the bacterium culture and incubated overnight at 37 °C.
Sarcosinate with a concentration of 1% was added and incubated for 2 h
at 37 °C. Sonication was performed 30 times, each time for a second,
with 10-s intervals, with the power of 20 kHz Mgcl2 (0.001M) was
added in order to inhibit EDTA. RNase and DNase were added at
300 μg/g of dry weight of bacteria and incubated 2 h at 37 °C.
Centrifugation was done at 5000 g for 30min at 4 °C for 30min. The
upper solution was removed and centrifuged at 40000 g for 30min at
4 °C (36).
2.4. Induction of recombinant vector with IPTG
E. coli BL21 containing pET-28a/cagA was dedicated by Dr. Esmaeili
(Associated Professor of BMSU). E. coli cells harboring expression vector
pET-28a/cagA were grown in LB medium supplemented with kana-
mycin (30 μg/ml) and chloramphenicol (34 μg/ml) at 37 °C to an OD
600=0.6–0.8 for induction, IPTG (Sigma, USA) was added to a ﬁnal
concentration of 1mM and for growth of bacteria were incubated at
37 °C for 4 h. The bacterial cells were harvested and suspended in lysis
buﬀer (Nacl 0.5M, PMSF 1mM, EDTA 10mM, 1%(v/v), Triton X-100,
20mM Tris- HCl, pH: 7.5) then was frozen, thawed and sonicated on ice
in the presence of PMSF 1mM (Sigma). Recombinant CagA proteins
were centrifuged at 14000 g for 20min and were collected in the su-
pernatant phase.
2.5. Immunizations and experimental studies
Four groups of mice (N = 12/groups) were immunized three times
in interval 14 days (0, 14, 28) subcutaneously with ﬁnal volume
0.1 mL (S.C). Immunizations were done with rCagA (10 μg) + CpG
(15 μg) [Group 1], OMP (10 μg) +CpG (15 μg) [Group 2], rCagA(5 μg)
+OMP(10 μg) + CpG (15 μg) [Group 3], PBS (0.1 Ml) [Group 4]. Sera
were collected 14 days after each immunization. ELISA was used to
measuring the serum IgG1, total IgG and IgG2a antibodies speciﬁc to H.
pylori antigens. Fourteen days after last immunization, mice were
challenged with 5×104 CFU of H. pylori SS1and B. abortus strain 544.
Antigen speciﬁc IL-4 and IFNγ responses were measured using ELISA kit
in spleen of immunized mice before and after challenge and also, IL-10,
IL-12 and TGFβ after challenge. The mice were killed and used to assay
naive splenocyte responses to stimulating desired antigens. Spleens
were sterility collected from mice. Spleens were removed and ground
through a screen mesh. The lysis of RBC in splenocyte samples were
performed by “ACK (Ammonium-Chloride-Potassium) lysis buﬀer”. Cell
suspensions of mice were washed, centrifuged and solution ﬁltered with
0.45 μm ﬁlter. Finally, lymphocytes were then resuspend at
5× 106 cells/ml in complete RPMI with 10% FCS [11]. Also gastric and
splenic tissues of mice were separated and placed in a plate, Then 1ml
of sterile saline was added to the plate and with the bottom of the
syringe was crushed the spleen, Then from serum and the liquid inside
plate, the dilution plates 1/10, 1/100 were prepared and cultured on
Brucella and blood agar media enriched with fetal calf serum that is
required for the growth of H. pylori. In temperature 37 °C with 10% CO2
for H. pylori and 5% CO2 for Brucella were incubated for 3–5 days. Then
the numbers of grown colonies in each group according to their dilu-
tions were calculated [12].
2.6. Study of serum and splenic bactericidal eﬀects
Mice spleen was isolated and their fragments cultured on Blood and
Brucella agar media. Serial dilution prepared and bacterial colonies
were counted as CFU based on pour plate count agar. Sera samples were
cultured on Brucella agar then bacteria count was carried out. H. pylori
cultures were performed on Brucella agar enriched with 5% deﬁ-
brinated sheep blood, FCS (Fetal calf serum) and incubated in micro-
aerophilic conditions.
2.7. RT- PCR
Primers were designed for detection of cytokines of IFNγ, IL-12, IL-4
and B.actin gene. Firstly, the whole sequence of the relevant genes was
searched from NCBI site, and primer design was performed by proper
online softwares. Forward and Reverse primers were blasted in the
Primer-BLAST section of NCBI BLAST Gene Bank [13]. In the next step,
primer pairs were studied by Oligo analyzer software. After this initial
stage and after examination and conﬁrmation of primers, they were
evaluated in silico PCR ampliﬁcation online software. After designing of
primers were ordered to the Pishgam Company for synthesis, after their
receiving, the primers were provided in eppendorf tubes lyophilized.
Deionized distilled water was used for diluting primers and they were
prepared with the appropriate concentrations. To prepare stock, the
primers were frizzed at−20 °C. Primer sequences used were as follows;
F IL-12: 5′ GGAAGCACGGCAGCAGAATA 3'; R-IL-12: 5′ AACTTGAGG
GAGAAGTAGGAATGG 3′(282 bp); F IFN-γ: 5′ ACTGGCAAAAGGATGG
TGAC 3'; R IFN-γ: 5′ TGAGCTCATTGAATGCTTGG 3′ (Amplicon 237
bp); F IL-4: 5′ GCCTGCTTTTCACATGAGGT 3'; R IL-4; 5′ AAATATGCG
AAGCACCTTGG 3′(Amplicon 250 bp); F B-actin: AGCCATGTACGTAG
CCATCC; R B-actin; CTCTCAGCTGTGGTGGTGAA (228 bp). After pre-
paring a stock solution, working solution 10 p.m from primers was
prepared. RT-PCR technique was applied to studying of gene expres-
sion.
2.8. Assay of IgG1 and IgG2α titer
IgG1 and IgG2α responses were measured in sera of immunized
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mice after challenge using ELISA test.
2.9. Statistical analysis
For comparison of responses between intra and inter groups of mice
and multiple groups, respectively, ANOVA and Tukey tests were used.
Two-way analysis of variance and LSD, using SPSS V13 statistical
software, compared the levels of proliferative responses to antigens.
The levels of proliferative responses to antigens were performed by two-
way analysis of variance and LSD. Values less than 0.05 were con-
sidered as a statistically signiﬁcant.
3. Results
3.1. The results of the clearance of bacteria in spleen
Mice spleens isolated and their fragments were cultured on proper
media. Colonies of Brucella were counted based on CFU (Fig. 1). The
statistical analysis also showed the signiﬁcant diﬀerences between test
groups compared to the control groups (p value˂0.01).
3.2. Serum clearance of Brucella
Sera samples were cultured on Brucella agar and then bacteria count
were carried out based on CFU (Fig. 2). The statistical results of the
analysis of spleen clearance show the signiﬁcant diﬀerences between
groups compared to the control groups (p value˂0.01).
3.3. Immunization reduced H. pylori colonization in mice gastric tissue
As was shown in Fig. 3, after challenge, mice were killed and gastric
samples were assessed and bacteria were counted based on CFU. The
results indicated that rCagA + OMP decreased bacterial colonization; a
signiﬁcant diﬀerence was seen between test and control groups (p
value˂0.001).
3.4. Clearance of Brucella and H. pylori in gastric, splenic and blood tissues
in mice
Clearance of Brucella and H. pylori was evaluated in serum, splenic
and gastric tissues of all mouse groups. Results indicated a higher
clearance of Brucella and H. pylori in the rCagA + TN-OMP + CpG
group compared with other groups (Fig. 4). Brucella count in blood and
spleen tissues decreased in all but the control group.
3.5. Results of expression of cytokines with RT-PCR technique
RT-PCR protocol was performed according to the material and
method section. For observation of results, the 1% agarose gel was used
(Fig. 5). As shown in Fig. 4, RT-PCR analysis before and after treatment
revealed that the gene expression of the IFNγ, IL-12 and IL-4 were
signiﬁcantly expressed in the presence of vaccine formulation while
these genes had higher expression in encountering of bacteria with
immunogens. Expression of B-actin housekeeping gene in test and
control groups remained relatively constant.
Fig. 1. The results of splenic clearance of Brucella in 4 mice groups. Results indicated that clearance of Brucella decreased in group rCagA + TN-OMP + CpG.
Fig. 2. The results of serum clearance of Brucella in 4 mice groups. Results indicated that clearance of Brucella decreased in group rCagA + TN-OMP + CpG.
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3.6. Results of IgG2α and IgG1 to TN-OMP + rCagA
Speciﬁc IgG1 and IgG2a isotypes were measured in sera after the
challenge. In this study the IgG2a/IgG1 ratio in the mice immunized
with rCagA and TN-OMP CpG was> 1, indicating a Th1 type response
that is important for clearance (Fig. 6). In other groups IgG2a/IgG1
ratio was<1 that indicated a humoral immune response.
4. Discussion
One of the major challenges associated with vaccines against bru-
cellosis is to increase their eﬀectiveness and safety. The live attenuated
vaccines for brucellosis are the S19 and Rev 1 types which are mostly
used in animals and have relatively good safety [14]. However, the
most important concern for these vaccines is their virulence in humans
[15]. OMPs of Brucella play a very important role in activating the host
immune system and have been introduced as a successful combination
vaccine candidate in humans and animals [16]. On the other hand, in
previous studies, recombinant OMP 31, 19, 16, 25 and 18 were used as
immunogenic antigens but none of them showed a successful clearance
[17,18]. For this reason, we used from total OMP of Brucella in this
study. Combination of OMP with the robust immunogenic protein
rCagA will raise the immunogenicity (humoral and cellular) against
Brucella and H. pylori together. Various factors of H. pylori have been
introduced as vaccine candidates but none has shown proper eﬃcacy
against this bacterium, and the eﬀectiveness of these vaccines are
limited [19]. Possibly, the appropriate immunity against H. pylori
Fig. 3. The results of gastric clearance of H. pylori in 4 mice groups. Results indicated that clearance of H. pylori decreased in group rCagA + TN-OMP + CpG.
Fig. 4. The total results of clearance of Brucella and H. pylori in serum, splenic
and gastric tissues of all mice groups. Gc: Gastric count, Sc: spleen count, Bc:
blood (serum) count. Results indicated that clearance of Brucella and H. pylori
decreased more than other groups in group rCagA + TN-OMP + CpG.
Fig. 5. Results of cytokine expression patterns with RT-PCR. Lane M. Marker
100 bp, lane 2 gene expression of IFNγ before immunization with TN-
OMP + rCagA + CpG combination, lanes 2 shows gene expression of IFNγ post
immunization with mentioned combination, lanes 3is correspond with gene
expression of IL-10 post immunization with desired combination, lanes 4 and 5
present gene expression of IL-4 after immunization with TN-
OMP + rCagA + CpG combination, lanes 6 and 7 show gene expression of IL-
12 after immunization with mentioned combination, lane 8 is related with gene
expression of B-actin Housekeeping gene before immunization and lane 9 is
associated with expression of B-actin Housekeeping gene post immunization
with the vaccine formulation.
Fig. 6. Results of assessment of IgG2α/IgG1 in group TN-OMP + rCagA + CpG
post challenge. This Figure indicates IgG2a/IgG1 ratio in group TN-
OMP + rCagA + CpG is > 1 that suggests a cellular immune response.
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obtained by combining the diﬀerent virulence factors with various ac-
tivities in pathogenesis of the infection [20]. The CagA and OMP are
among the most important virulence factors and the major protective
antigens, and they have been applied in vaccination experiments to
inhibit H. pylori and Brucella infection in mouse model [21], in present
study we used from Brucella total OMP as a basic antigen factor ac-
companied by H. pylori rCagA. The study conducted by Rossi et al.
showed that the use of a combination (CagA, VacA, and NAP) can
considerably reduce the colonization rate of H. pylori in gastric tissue
[22]. In line with above study, our study revealed that the combination
(CagA-OMP) decreases the numbers of bacteria in gastric tissue after
challenge with H. pylori. Again, a study carried out by Esmaeili et al.
emphasized that the combination (CagA-LPS) dramatically reduced the
colonization of H. pylori in gastric mucus, which is due to the strong
Th1 response, 6-fold reduction in the numbers of H. pylori in the gastric
tissue compared to non-immunized mice has been observed in pro-
tected mice of infection with H. pylori [23].
In another study by Siadat et al. an LPS was conjugated with an
OMP (outer membrane vesicles of meningococci), results revealed that
the LPS of this bacterium is an important virulent factor, which is able
to escape from the immune system by creating a balance between Th1
and Th2. They concluded that this conjugate is capable of Th1 stimu-
lation and Th2 inhibition. They also showed that immunization with
Brucella LPS alone may result in a meaningful induction of IFN-γ
compared with OMV + LPS and FA + LPS groups (p > 0.5), although
titers IL-4 and IL-10 slightly increased, whereas in the conjugated
vaccine, the values of IL-4 and IL-10 were greater [24,25]. In a study by
Stein et al., in 2009, it was shown that BLS Omp31 (Brucella spp.
Omp31) induced a protective IFN-γ and IgG response against B. ovis in
male sheep [26]. rCagA 32 KD is a hydrophilic, surface-exposed antigen
that induces cellular and humoral immunity responses. The H. pylori
serotype O2 is unique, because does not express Lewis antigen but also
induces a strong Th1 immune response which aids in the protection or
clearance against H. pylori infection [27,28]. Conjugation of these
proteins with rCagA as an adjuvant which is a strong immunogenic
protein will increase the immune response against TN-OMP [29].
Mentioned studies with our study present the fundamental role of
rCagA and related combinations in inducing of immunity and protec-
tion against H. pylori and Brucella. The signiﬁcantly low values of IL-4
and IL-10 compared with IFN-γ in all groups indicated this formulation
induced Th1 response, which can be considered as an important factor
in the eﬃciency of the Brucella vaccine. After immunization in the
animal model, the value of IFN-γ in relation to IL-4 and IL-10 were
expressed in all groups, indicating an appropriate cellular immune re-
sponse through TH1 and the secretion of IFN-γ. The results of our study
showed that the TN-OMP along with rCagA protein is a successful
candidate for immunization.
IgG2a titers predominated over IgG1 titers during immunization
with antigens TN-OMP along with rCagA protein. The induction of a
speciﬁc IgG2a subclass during an immune response is also aﬀected by
the Th1/Th2 balance. The simultaneous use of TN-OMP and rCagA
along with CpG has a synergistic eﬀects and promotes a Th1 immune
response (IFN-γ, IL-12, IgG2a), which aids in the protection and
clearance of the H. pylori infection. Clearance was associated with high
levels of IFN-γ and IgG2a. The balance between Th1/Th2 responses is
essential for the clearance of H. pylori. Th2 responses are needed for
suﬃcient antibody production. However, Th1 responses are seen to
occur more often in natural cases of H. pylori and Brucella infections.
Formation of antigen-antibody complexes facilitates neutralization
and opsonization of the pathogen, which can also lead to the neu-
tralization of the CagA toxin. Because OMP induces humoral and cel-
lular immunity, we selected it for immunization accompanied with
rCagA. The results demonstrated that a combination of OMP + rCagA
induced a higher cellular and humeral immune response than any of
them alone.
Due to the adverse side eﬀects of attenuated vaccines against
Brucella, it is necessary to explore alternative vaccination options.
Subunit vaccines are safer, so we can use appropriate antigens for im-
munization. The search for a suitable vaccine for use in humans is re-
quired, because there is also biological warfare. Researchers have so far
investigated LPS, r OMP and OMP as conjugated or accompanied by
other proteins, but in this study we select a 32 KD fragment of CagA
without EPIYA motif combined TN-OMP.
Nowadays, Brucellosis is a global problem. With the exceptions of a
small number of countries that have eradicated Brucellosis or have no
incidence of it, most countries are aﬀected. In the latest report from
WHO, only 17 countries in the world have no incidence of Brucellosis.
In the Eastern Mediterranean and Middle East, all countries were af-
fected and Iran is one of the endemic regions with a high incidence of
both animal and human Brucellosis. Statistically, the economic losses
due to the animal and human Brucellosis have been estimated to be
very high in Iran. The lack of an eﬀective human vaccine and the ad-
verse side eﬀects of animal vaccines are reasons why this disease has
not yet been eradicated on a global scale. Appropriate immune against
Brucella are based on the cellular immune responses. In other words,
enhancing the killing power of macrophages depends on the secretion
of cytokines like IFN-γ. Therefore, it is essential to select an appropriate
antigen capable of inducing cellular responses to eradicate this bac-
terium from the body tissues.
Given that rCagA is a hydrophilic protein, it enhanced the immune
response. In other studies, an OMP with a weaker immune response has
commonly been used. Therefore, in this study we propose the use of TN-
OMP without signiﬁcant conformational alterations as an immunization
candidate, due to the fact that total proteins are exposed and are cap-
able of inducing a potent immune response. Furthermore, a TN-OMP
with hydrophilic protein can play a more eﬀective role in enhancing
humoral and cellular responses.
The present study showed that the total outer membrane protein
that is naturally produced has a conformational structure with suitable
epitopes that stimulate cellular and humoral immunity. Conjugating the
antigenic epitopes may also be changed and reduce the immune re-
sponse.
Hence, the literature shows that rCagA and Brucella OMP can be
suitable candidates for vaccines. Due to the changes and diversity in the
C-terminal segment of CagA gene in various isolations of H. Pylori, in
this study we used a protected N-terminal segment with antigenic and
immunogenic properties, to induce an appropriate immune response.
Because this segment is protected and has suitable folding properties, it
can induce a better immune response.
5. Conclusion
Our results showed that the vaccine combination was eﬀective
against an oral exposure and the bacterial burden in the spleen, serum,
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